Skip to main content

Table 3 Tolerability of subgroups

From: Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer

  n Treatment completion rate (%) Relative dose intensities(%)
  6 cycle (%) 8 cycle (%) mean median
  S-1 (%) Oxaliplatin (%) S-1 (%) Oxaliplatin (%)
Age(years)     
< 55 27 20(74.07) 15(55.56) 68.74(98.20) 124.11(95.47) 68.00(97.14) 127.00(97.69)
55~ 65 23 16(69.57) 9(39.13) 69.60(99.43) 123.74(95.18) 70.00 (100.00) 125.00 (96.15)
≥65 4 3 (75.00) 2 (50.00) 69.75 (99.64) 116.25 (89.42) 70.00 (100.00) 116.50 (89.62)
Gender
Male 37 25 (67.57) 17 (45.95) 69.38 (99.11) 122.32 (94.10) 70.00 (100.00) 124.00 (95.38)
Female 17 14 (82.35) 9 (52.94) 68.77 (98.24) 125.65 (96.65) 68.00(97.14) 129.00 (99.23)
PS(ECOG)
0 14 10 (71.43) 6 (42.86) 68.64 (98.06) 125.29 (96.37) 68.50 (97.86) 127.50 (98.08)
1 40 29 (72.50) 20 (50.00) 69.38 (99.11) 122.70 (94.38) 70.00 (100.00) 123.00 (94.62)
BSA
< 1.7 26 22 (84.62) 13 (50.00) 70.85 (101.21) 123.96 (95.36) 71.00 (101.43) 125.00 (96.15)
≥1.7 28 17 (60.71) 13 (46.43) 67.64 (96.63) 122.82 (94.48) 68.00(97.14) 126.00 (96.92)
Type of gastrectomy
Total 9 7 (77.78) 4 (44.44) 70.33 (100.48) 121.22 (93.25) 71.00 (101.43) 119.00 (91.54)
Partial 45 32 (71.11) 22 (48.89) 68.96 (98.51) 123.80 (95.23) 68.00(97.14) 126.00 (96.92)